Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults

Journal of the American Geriatrics Society

Volumn 63, Issue 10, 2015, Pages 2070-2073

  Hinson, Andrew M ^a,b   Wilkerson, Bekka M ^b   Rothman Fitts, Ivy ^b   Riggs, Ann T ^b   Stack, Brendan C ^a   Bodenner, Donald L ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

bisphosphonates; elderly; fracture; hyperparathyroidism; PPIs

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CREATININE; ESOMEPRAZOLE; IBANDRONIC ACID; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PARATHYROID HORMONE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CREATININE BLOOD LEVEL; GERIATRIC HOSPITAL; HUMAN; HYPERPARATHYROIDISM; KIDNEY FUNCTION; LONG TERM CARE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OUTPATIENT CARE; PARATHYROID HORMONE BLOOD LEVEL; TREATMENT DURATION; VITAMIN BLOOD LEVEL; AGED; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; MIDDLE AGED; RETROSPECTIVE STUDY;

AGED; CALCIUM; CREATININE; DIPHOSPHONATES; HUMANS; HYPERPARATHYROIDISM; MIDDLE AGED; PARATHYROID HORMONE; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; VITAMIN D;

EID: 84944558432     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.13661     Document Type: Article

References (27)

1. FDA Drug Safety Communication. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. US Department of Health and Human Services [on-line]. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm Accessed November 23, 2014.
2. Yang YX, Lewis JD, Epstein S, et al., Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-2954.
3. McCarthy DM,. Adverse effects of proton pump inhibitor drugs: Clues and conclusions. Curr Opin Gastroenterol 2010; 26: 624-631.
4. Pasina L, Nobili A, Tettamanti M, et al., REPOSI Investigators. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med 2011; 22: 205-210.
5. Leontiadis GI, Moayyedi P,. Proton pump inhibitors and risk of bone fractures. Curr Treat Options Gastroenterol 2014; 12: 414-423.
6. Vestergaard P, Rejnmark L, Moseklide L, et al., Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006; 79: 76-83.
7. Targownik LE, Lix LM, Metge CJ, et al., Use of proton pump inhibitors and risk of osteoporosis-related fractures. Can Med Assoc J 2008; 179: 319-326.
8. Targownik LE, Lix LM, Leung S, et al., Proton pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896-904.
9. Gray SL, LaCroix AZ, Larso J, et al., Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women. Arch Intern Med 2010; 170: 765-771.
10. O'Connel MD, Madden DM, Murray AM, et al., Effects of proton pump inhibitors on calcium carbonate absorption in women: A randomized crossover trial. Am J Med 2005; 118: 778-781.
11. Costa-Rodrigues J, Reis S, Teixeira S, et al., Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J 2013; 280: 5052-5064.
12. Mendenhall W, Beaver RJ, Beaver BM,. Introduction to Probability and Statistics, 14th Ed. Boston: Brooks/Cole, Cengage Learning, 2013.
13. Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al., Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: A randomized, crossover, controlled trial. J Bone Miner Res 2010; 25: 2205-2211.
14. Keller J, Schinke T,. The role of gastrointestinal tract in calcium homeostasis and bone remodeling. Osteoporos Int 2013; 24: 2737-2748.
15. Yu EW, Blackwell T, Ensrud KE, et al., Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008; 83: 251-259.
16. Moayyedi P, Leontiadis GI,. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol 2012; 9: 132-139.
17. Mizunashi K, Furukawa Y, Katano K, et al., Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993; 53: 21-25.
18. Pitt SC, Sippel RS, Chen H,. Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin North Am 2010; 89: 1227-1239.
19. Koop H, Klein M, Arnold R,. Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther 1990; 4: 131-138.
20. Gagnemo-Persson R, Hakanson R, Sundler F, et al., Growth of the parathyroid glands in omeprazole-treated chickens. Scand J Gastroenterol 1994; 29: 493-497.
21. Jobke B, Milovanovic P, Amling M, et al., Bisphosphonate-osteoclasts: Changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Bone 2014; 59: 37-43.
22. Hinson AM, Smith CW, Siegel ER, et al., Is bisphosphonate-related osteonecrosis of the jaw an infection? A histological and microbiological ten-year summary. Int J Dentistry 2014; 2014: 452737.
23. Hinson AM, Siegel ER, Stack BC Jr,. Temporal correlation between bisphosphonate termination and symptom resolution in osteonecrosis of the jaw: A pooled case report analysis. J Oral Maxillofac Surg 2015; 73: 53-62.
24. Mattsson JP, Vaananen K, Wallmark B, et al., Omeprazole and bafilomycin, two proton pump inhibitors: Differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta 1991; 1065: 261-268.
25. Zaidi M,. Skeletal remodeling in health and disease. Nat Med 2007; 13: 791-801.
26. Abrahamsen B, Eiken P, Eastell R,. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011; 171: 998-1004.
27. Lee J, Youn KE, Choi NK,. A population-based case-control study: Proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol 2013; 48: 1016-1022.